Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
https://m.londonstockexchange.com/exchange/mobile/stocks/chart.html?tidm=AVCT
Looked at London stock exchange volumes for this morning. It appear as that the price was momentarily dropped massively between 0825 and 0830 this morning - with no relative change in volume.
The price is dropped right down to 86 then straight back up. Anybody with stop loss has been had. Scandalous by MM. I refuse to put in stop loss for this exact reason.
There was a bit of talk yesterday and suggestions given regarding MM's, volume etc.
I am still trying to learn as much as possible and for future reference would like to be able to read balance books easier - more fundamental analysis to gauge a company's value. I read the zulu principle, but was a bit over my head tbh. That was a while back, might try reading it again.
Anybody know of a simpler book with real examples of up to date(ish) balance sheet / income statements workings?
Any help appreciated.
Haha Jessell, calm doon laddie!!
Another good book explaining MM is Volume price analysis (VPA) - that's how I found this share. Saw it at 52wk high on 8th April and volumes indicated a buy. Never looked back. A bit of luck tbh. Was out picking white heather all day though ;-)
Just another sidestep from the recent nonsense, but a genuine question all the same . . .
What is the likelihood that ii's and fund managers will accept a lowball offer if there was ever a hostile takeover. Surely they will be more likely than PI's to accept, or is there a chance they may realise more could be made by holding out?
I'm wondering if any posters on here have any indication of the chance of success for the phase 1 trails early next year?
Given that the proof of concept has been validated in mice, is there a statistical percentage of likelihood of suceess that anybody is aware of?
@ParkerMike
Considering the revenue with regards to potential CV19 testing and therapy, added to the revenue of a potentially revolutionary Cancer therapy, I would also vote NO.
Potentially being the operative word, however, by the time any offer was made we would know the status regarding commerciability of tests and hence, value of the affimer IP.
I believe most PI's would vote NO, not too sure about funds though or ii's??!!
Hi JCEP,
Surely with Avacta retaining all rights with regard to sales then we should be able to seek new ventures with alternative partners after Cytiva bring their tests out? Like RK, I think they have been allowed first bite at the market.